BioCentury | Aug 23, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers A three-protein signature in tumor-infiltrating lymphocytes (TILs) could help predict response to PD-1 and PD-L1 inhibitors in NSCLC. In pre-treatment tumor samples from 39 NSCLC patients treated with PD-1 or PD-L1 inhibitors,...
BioCentury | Jun 14, 2018
Tools & Techniques

Imaging immunotherapy

Stanford University researchers have made an imaging agent that detects activated T cells and could predict whether a patient will respond to immunotherapy within days of treatment. Typically, it takes weeks to months to determine...
BioCentury | May 30, 2018
Preclinical News

Tet2 disruption improves Kymriah efficacy

In a Nature study , researchers at the University of Pennsylvania identified a patient with an enhanced response to CAR T therapy Kymriah tisagenlecleucel, and suggested targeting the epigenome by inhibiting Tet2 could improve the efficacy...
BioCentury | Apr 6, 2018
Clinical News

Bio-Path reports interim Phase II data for AML candidate

...Houston, Texas Product: Prexigebersen (BP1001) Business: Cancer Molecular target: Growth factor receptor-bound protein 2 (GRB2) Description: Liposomal antisense inhibitor of GRB2...
...duration of response, safety and pharmacokinetics Status: Interim Phase II data Milestone: NA Sandi Wong cytarabine prexigebersen Bio-Path Holdings Inc. Growth factor receptor-bound protein 2 (GRB2)...
BioCentury | Feb 21, 2018
Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest inhibiting CHI3L1 could help treat lung metastases of melanoma. In mouse melanoma cells co-cultured with mouse CD8 + T cells, CHI3L1 knockout in the T cells increased...
BioCentury | Oct 27, 2017
Preclinical News

Cell study points to new antibiotic strategy

A study in Cell shows granzyme B (GrB; GZMB), an immune cell protease, kills diverse bacterial species by shutting down multiple conserved survival pathways. The authors suggest compounds that mimic the protease’s mechanism could treat...
BioCentury | Aug 9, 2017
Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; breast cancer Patient sample, cell culture and mouse studies suggest inhibiting HDAC1 alone or in combination with T cell therapies could help treat NANOG -positive cervical and breast cancers. In cervical cancer...
BioCentury | Nov 30, 2016
Distillery Therapeutics

Hematology; other

INDICATION: Bone marrow transplant (BMT); poisoning Mouse studies suggest inhibiting GRB10 could enhance the efficacy of BMT and help treat radiation injury. In mice exposed to sublethal doses of total body irradiation, heterozygous GRB10 knockout...
BioCentury | Nov 4, 2016
Clinical News

BP1001: Ph II started

...Liposomal Grb-2 (BP1001) (formerly BP-100-1.01) Business: Cancer Molecular target: Growth factor receptor-bound protein 2 (GRB2) Description: Liposomal antisense inhibitor of GRB2...
...duration of response, pharmacokinetics and safety Status: Phase II started Milestone: NA Julian Zhu BP-100-1.01 BP1001 Liposomal Grb-2 Bio-Path Holdings Inc. Growth factor receptor-bound protein 2 (GRB2)...
BioCentury | Jun 13, 2016
Clinical News

Liposomal Grb-2: Additional Phase I data

...BP1001 ) (formerly BP-100-1.01 ) Business: Cancer Molecular target: Growth factor receptor-bound protein 2 (GRB2) Description: Liposomal antisense inhibitor of growth factor receptor-bound protein 2 (GRB2)...
Items per page:
1 - 10 of 36